Invitrogen, AB postpone merger
Thursday, 16 October, 2008
The merger between scientific equipment giants Invitrogen and Applied Biosystems has been delayed due to the slumping global market.
Shareholders had been scheduled to meet today to vote to finalise the merger.
But the deal, which was originally worth around US$7 billion, has been devalued to US$5.5 billion due to the sharp decline in the value of Invitrogen shares due to the stock market crisis.
In a joint statement, the two companies said there were also tax issues to be overcome before the merger goes ahead, which both are confident will happen.
The proposal will be discussed at a general meeting on October 28. Both companies expect the deal to go ahead as planned, and be complete by the end of November.
COVID vax linked to smaller risk of heart problems than infection
The risk of rare heart complications following COVID-19 vaccination in children was found to be...
Ancient lead exposure shaped human evolution
An international study claims that exposure to lead may have influenced the evolution of hominid...
Reproductive impacts of PFAS exposure revealed
New studies have found that PFAS exposure can significantly alter male reproductive health, and...
